Benzinga | Nov 5, 2020 05:48PM EST

Nektar Therapeutics Q3 EPS $(0.61) Beats $(0.74) Estimate, Sales $30.03M Beat $26.33M Estimate

Nektar Therapeutics (NASDAQ:NKTR) reported quarterly losses of $(0.61) per share which beat the analyst consensus estimate of $(0.74) by 17.57 percent. This is a 8.93 percent decrease over losses of $(0.56) per share from the same period last year. The company reported quarterly sales of $30.03 million which beat the analyst consensus estimate of $26.33 million by 14.06 percent. This is a 2.79 percent increase over sales of $29.22 million the same period last year.